40 results about "Fluorouracilum" patented technology

This invention relates to a pharmaceutical composition for tumor treatment and its application. Specifically, this invention relates to a composition containing a fluorouracil drug and pyrimidine nucleosides and their derivatives. Fluorouracil drugs and pyrimidine nucleotides and their derivatives have a synergistic antitumor effect; combined use can reduce the concentration of single drugs and achieve better antitumor efficacy, while reducing toxic side effects.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

The application relates to a synthesis method of red luminescent carbon dots with a targeting diagnosis and treatment potential of hepatocellular carcinoma, which comprises the following steps: 1) adding 5-fluorouracil and indocyanine green into deionized water, uniformly mixing, and forming a uniform mixed solution; 2) heating the mixed solution obtained in the step 1) at 160-200 DEG C for 5-9 h, and cooling to room temperature; 3) filtering and dialyzing the solution obtained in the step 2), and obtaining a pure 5-FICD solution; and 4) freeze-drying the solution obtained in the step 3), and obtaining the product. The method takes anticancer drug 5-fluorouracil and photosensitizer indocyanine green as precursors, synthesizes a low-toxicity red light carbon dot through a simple hydrothermal method, improves the shortcoming that a chemotherapy drug has a large side effect, and realizes the targeted killing of hepatocellular carcinoma cells.

The application belongs to the technical field of medicine preparation, and particularly relates to a magnetic layered double hydroxide, a targeted drug-loaded nano preparation, a preparation method and application of a tumor-targeted drug-loaded nano preparation. The preparation method of the magnetic layered double hydroxide provided by the application can prepare Fe3O4 nanoparticles with small particle size, and further prepare the magnetic layered double hydroxide which can be used as a water-soluble drug carrier. The magnetic layered double hydroxide is used for preparing the targeted drug-loaded nano preparation and the tumor-targeted drug-loaded nano preparation, and can be used for delivering water-soluble drugs such as 5-fluorouracil. The tumor-targeted drug-loaded nano preparation has good dispersity and can be actively targeted to HepG2 cells with high FR expression, has a good inhibitory effect on liver cancer cells, and is expected to provide a potential new treatment system for magnetic chemotherapy.

This invention provides a sample pretreatment method and identification method for identifying ginseng polysaccharides in compound fluorouracil oral solution, belonging to the field of pharmaceutical detection and analysis technology. The sample pretreatment method of this invention includes: centrifuging the compound fluorouracil oral solution and taking the clear solution; adding silica gel to the clear solution, mixing, and removing the solvent to obtain a solid mixture; adding ethanol solution or anhydrous ethanol to the obtained solid mixture, heating and refluxing, discarding the ethanol solution, and obtaining the residue; adding water to the obtained residue, sequentially extracting and centrifuging, taking the supernatant obtained by centrifugation, removing the solvent from the supernatant, and then redissolving it with water; the identification method of this invention is thin-layer chromatography analysis, and the developing solvent includes the following components in parts by volume: 6.8-9.2 parts of n-propanol, 1.76-2.24 parts of water, 0.75-1.24 parts of ethyl acetate, and 0.75-1.24 parts of glacial acetic acid. The sample pretreatment method and identification method for identifying ginseng polysaccharides in compound fluorouracil oral solution of this invention have high specificity.

The invention specifically discloses a PreTA inhibitor and application thereof, and relates to the technical field of biological medicines. The inhibitor provided by the invention can be used for effectively inhibiting the activity of PreTA, so that the anti-tumor effect of 5-fluorouracil (5-FU) is recovered.

The application discloses a method for catalytically producing 5-fluorouracil and application, and belongs to the technical field of biology. The method uses 5-fluoroorotic acid as a substrate and orotidine-5'-phosphate decarboxylase as a catalyst to efficiently catalyze the synthesis of 5-fluorouracil. The catalytic efficiency is further improved by molecular modification of orotidine-5'-phosphate decarboxylase, the efficient and green production of 5-fluorouracil is realized, and the application of 5-fluorouracil in the fields of medicine and the like is promoted.

The application relates to a pharmaceutical cocrystal of cytarabine and 5-fluorouracil and a preparation method thereof, and relates to the technical field of pharmaceutical cocrystals. The pharmaceutical cocrystal is composed of one cytarabine molecule and one 5-fluorouracil molecule as a basic structural unit, and has a chemical formula of [C9H 13 N3O5.C4H3N2O2F]; the pharmaceutical cocrystal belongs to an orthorhombic system and has a space group of P212121. The pharmaceutical cocrystal prepared by a solvent evaporation method and a cooling method improves the permeability of cytarabine, appropriately reduces the solubility of cytarabine, and significantly improves the antitumor activity of cytarabine; through the complementary advantages of the properties and the pharmacodynamic effects of two components, the synergistic antitumor effects of cytarabine and 5-fluorouracil are realized, and a new idea is provided for developing synergistic antitumor pharmaceutical cocrystals. The pharmaceutical cocrystal can keep the skeleton structure of the crystal unchanged after long-term placement at room temperature, the preparation method is simple and easy to implement, the cost is low, and the pharmaceutical cocrystal is convenient for large-scale production.

The invention discloses synthesis and antitumor activity research of a novel drug small molecular formula (1) containing an indole structure, wherein R is as follows: 5-acetylvaleric acid is used as a starting raw material, then Fischer reaction, methylation reaction and hydrolysis reaction are performed to obtain 4-(5-(tert-butyl)-1, 2-dimethyl-1H-indole-3-yl) butyric acid, and the 4-(5-(tert-butyl)-1, 2-dimethyl-1H-indole-3-yl) butyric acid is used as a raw material. The compound is coupled with different amine compounds to obtain a target compound. A target compound is subjected to a CCK-8 experiment, and a conclusion is obtained that the target compound 6f and 5-fluorouracil are tested at the concentration of 20 [mu] M within 6a-6 h, and it can be known that the compound 6f has the best inhibition effect on A549 cells, Hela cells and A549 cells. IC50 value calculation is carried out on a target compound under various concentrations, the IC50 value of 6c to Hep G2 cells is minimum and the inhibition effect is best, and the IC50 value of 6f to A549 cells and Hela cells is minimum and the inhibition effect is best.

Disclosed are method of treating a subject in need thereof comprising applying an alternating electric field, at a frequency for a period of time, to a target site of the subject in need thereof; and administering a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin to the subject in need thereof. Disclosed are methods of reducing viability of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin. Disclosed are methods of increasing apoptosis of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cancer cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin. Disclosed are methods of reducing the number of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cancer cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin.

This invention discloses a method for scalable preparation of 5-fluorouracil-loaded lyophilized nanoparticles. The method first involves self-assembling 5-fluorouracil into a polymer carrier to form core-shell nanoparticles. Then, the hydrophobic core-shell nanoparticles undergo a double emulsification-isothermal evaporation process to form hydrophilic micro / nanoparticles. Finally, D-mannose is assembled onto the surface of the micro / nanoparticles, followed by gradient freeze-drying to prepare PLGA / 5-FU-loaded lyophilized nanoparticles. This method offers advantages such as simple operation, scalability, and good reproducibility. The 5-FU drug in the prepared lyophilized nanoparticles exhibits good crystallinity. During the inhibition of pancreatic cancer cell growth, it effectively improves the bioavailability, biocompatibility, and physical stability of 5-fluorouracil, significantly inhibiting pancreatic cancer cell growth and demonstrating high anti-tumor immunomodulatory properties.

The invention relates to an oligonucleotide lung targeting delivery system and application thereof in treatment of lung diseases, and relates to the technical field of biological medicines and nano-medicines. The invention designs a high-efficiency lung targeting oligonucleotide delivery drug, which comprises lipid nanoparticles, the lipid nanoparticles contain oligonucleotide and lipid components, and the lipid components are composed of 4-(N, N-dimethylamino) butyric acid (dilinoleyl) methyl ester, (2, 4-dimethylamino) butyric acid (dilinoleyl) methyl ester, (2, 4-dimethylamino) butyric acid (2, 4-dimethylamino) butyric acid (2, 4-dimethylamino) butyric acid (2, 4-dimethylamino) butyric acid (2, 4-dimethylamino) butyric acid The composition is composed of 1, 3-dioleoyl-propyl)-trimethylamine, dipalmitoyl phosphatidylcholine and pegylated lipid. A breakthrough of a nucleic acid medicine lung delivery technology is realized, in-vivo experiment verification results show that the lung aggregation efficiency is improved by about 2-4 times compared with that of traditional lipid nanoparticles, the lipid nanoparticles have remarkable lung metastatic tumor resisting activity, in-vivo experiments show that the lipid nanoparticles can inhibit growth of colorectal cancer lung metastatic tumors and prolong the survival time of mice, and the lipid nanoparticles have good application prospects. And the effect is better than that of 5-fluorouracil and regorafenib.

The invention discloses an integrated electrochemical membrane reactor based on in-situ deep purification of high-salinity wastewater and a water treatment method of the integrated electrochemical membrane reactor. A ceramic membrane is used as a substrate, an iron-based non-metal coordination porous carbon active layer modified on the surface is used as a cathode, and the integrated electrochemical membrane reactor with catalytic oxidation and filtering functions is jointly formed by the ceramic membrane and an anode. The method is suitable for treating high-salt and degradation-resistant organic wastewater, can efficiently remove more than 90% of typical pollutants such as 5-fluorouracil and stably remove more than 50% of wastewater COD (Chemical Oxygen Demand) in a continuous flow operation mode, has the advantages of high catalytic activity, stable structure, flexible operation mode and the like, and is suitable for industrial production. And an efficient and reliable technical solution is provided for deep purification of the high-salt degradation-resistant wastewater.

The invention discloses a drug-loaded microgel-gel sustained-release dressing as well as a preparation method and application of the drug-loaded microgel-gel sustained-release dressing. The dressing comprises a drug microgel phase loaded by GelMA microspheres and a hydrogel shell phase formed by copolymerizing CSMA and a double-bond-containing micromolecule cross-linking agent, and can be polymerized and cured in situ through ultraviolet light. The carried medicine comprises one of bevacizumab, triamcinolone acetonide and fluorouracil, and multi-medicine synergistic slow release is achieved. The dressing provided by the invention has good biocompatibility, degradability, shape adaptability and slow release performance, can significantly improve local drug concentration, reduce administration frequency and improve patient compliance, and is suitable for treatment and repair of keloid.

This invention discloses an acylhydrazone compound containing a quinazolinone fragment, its preparation method, and its application, relating to the field of medicinal chemistry. The acylhydrazone compound containing the quinazolinone fragment, or its pharmaceutically acceptable salt, isomer, hydrate, solvate, crystal form, or prodrug, has the following structural formula. This invention designs and synthesizes acylhydrazone compounds containing a quinazolinone fragment using the principle of combination, and tests these compounds on their anticancer activity, screening out compounds with anticancer activity superior to 5-fluorouracil.

Functionalized nanoparticle composition comprising 5-fluorouracil for enhanced anticancer activity, the composition comprising: a. 5-Fluorouracil at a quantity of 10.00% w / w, configured as an active anticancer agent; b. Poly(lactic acid-co-glycolic acid) at a quantity of 60.00% wt / w, configured to encapsulate the 5-fluorouracil and form a biodegradable nanoparticle matrix; c. Polyethylene glycol (PEG-2000) in an amount of 10.00% (w / w) configured to functionalize the surface of the nanoparticles and improve stability and bioavailability; d. Chitosan at a quantity of 5.00% (wt / wt), configured to effect surface modification and improve cellular uptake and targeting accuracy; e. Polyvinyl alcohol in an amount of 3.00% wt / wt, configured as a stabilizing and emulsifying agent during nanoparticle formation; f. Tween 80 at a concentration of 2.00% w / w, configured to improve dispersion stability and control particle size; and g. Mannitol at a quantity of 10.00% w / w, configured as a cryoprotectant to enhance stability during lyophilization and storage; the composition offering improved drug incorporation efficiency, delayed drug release, improved bioavailability, and enhanced anticancer activity compared to non-functionalized formulations of 5-fluorouracil.

The invention relates to a platinum folinate protein nanoparticle as well as a preparation method and application thereof. The platinum folinate protein nanoparticle consists of a complex and protein, wherein the complex is formed by platinum drug precursor ions (cyclohexanediamine platinum dihydrate ions and / or diamine platinum dihydrate ions) and folinate ions. The protein nanoparticle is prepared in an aqueous solution with the room temperature and the pH value of 7.5, the folinate platinum encapsulation efficiency is 70%-99%, the drug loading capacity is 3%-30%, the platinum utilization rate is 5%-30%, the protein nanoparticle has the pH response drug release characteristic, folinate and oxaliplatin or cis-platinum with anti-tumor activity can be released at the same time in a weak acid environment, and the drug curative effect and the body tolerance and safety can be remarkably improved. In addition, the protein nanoparticles and 5-fluorouracil can play a synergistic anti-tumor effect, and a better treatment effect is shown.

The invention discloses application of probiotics in preparation of medicines for treating colorectal cancer, and belongs to the technical field of biological medicines. According to the preparation method disclosed by the invention, the oral capsule preparation is prepared by using the probiotics Kazachstania pintolopesii, Kazachstania pintolopesii thalli are treated into powder through methods such as freeze drying or spray drying and the like, and the powder is packaged into the capsule, so that the thalli can be stably released in gastrointestinal tracts, and the immunoregulation and anti-tumor effects are achieved. Animal experiments and clinical tests prove that the Kazachstana pintolopesii probiotic capsule disclosed by the invention not only enhances the anti-tumor immune effect of chemotherapy, but also can improve the tolerance of a colorectal cancer patient in the fluorouracil chemotherapy process, reduce the side effect of chemotherapy, improve the life quality of the colorectal cancer patient, and has a good application prospect. And a safer and more effective treatment scheme is provided for colorectal cancer patients.

The invention discloses synthesis and antitumor activity research of a novel drug small molecular formula (1) containing an adamantane structure. According to the invention, 1-bromoadamantane is used as an initial raw material, 2-(4-((3R, 5R, 7R)-adamantane-1-yl)-2-nitrophenoxy) acetic acid is generated through a typical Friedel-Crafts alkylation reaction, an NBS bromination reaction and the like, and then an important intermediate compound 5 is synthesized through a Wittig reaction and a hydrolysis reaction. And carrying out coupling reaction on the intermediate compound 6 and different amine compounds to obtain eight target compounds 7a-7h: formula (1). A CCK-8 experiment is carried out on a target compound to obtain a conclusion that the target compound 7a-7f and 5-fluorouracil are tested at the concentration of 20 mu M, and the result shows that the compound 7c has the best inhibition effect on HeLa and A549 cells, and the compound 7e has the better inhibition effect on Hep G2 cells. IC50 value calculation is carried out on a target compound under various concentrations, the IC50 value of 7c on HeLa and A549 cells is minimum and the inhibition effect is best, and the IC50 value of 7e on Hep G2 cells is minimum and the inhibition effect is best.

The invention discloses an anesthesia pump flow velocity abnormity automatic alarm device and method for fluorouracil continuous infusion, and relates to the field of anesthesia pump flow velocity abnormity detection.The anesthesia pump flow velocity abnormity automatic alarm device comprises a detection protection mechanism used for detecting the flow velocity of a continuous infusion anesthesia pump, and the detection protection mechanism comprises a detection plate box; a mounting cavity is formed in the detection plate box, a plurality of telescopic elements are fixedly connected to the interior of the mounting cavity, and one end of each telescopic element is connected with an arc-shaped detection plate; according to the anesthesia pump abnormal flow speed automatic alarm device and method for fluorouracil continuous infusion, through the effect of a clamping and containing mechanism, after detection is completed, a first rotating plate and a second rotating plate can be contained in a first containing groove and a second containing groove correspondingly; through the flexible storage mode, the occupied space of the two sides of the detection plate box is greatly reduced, a worker can conveniently store the detection plate box, and the portability and practicability of the equipment are improved.

The invention discloses a pH-responsive drug delivery agent based on a copper-based metal organic framework as well as a preparation method and application thereof, and belongs to the technical field of biomedical materials. The delivery agent is prepared by taking MOF-199 as a carrier and loading an anti-cancer drug 5-fluorouracil (5-Flu) through an in-situ stirring method. The preparation method is simple, and the drug loading efficiency is high. The delivery system realizes intelligent drug release by using the acidic characteristic of a tumor microenvironment: under the simulated tumor acidic condition of pH 5.0, the cumulative drug release rate within 50 hours reaches 74.64%, which is significantly improved compared with a neutral environment (pH 7.4); the release mechanism of the compound is derived from acid-triggered Cu-O bond hydrolysis and phosphate radical competitive coordination. Biological evaluation shows that the drug carrier has higher than 80% of high biocompatibility for normal cells (Raw264.7), and has a remarkable inhibition effect on proliferation of meibomian adenocarcinoma cells (SCG) at the same time. The invention provides a new strategy for developing an anti-cancer drug delivery system with strong targeting property and high safety.

The invention belongs to the technical field of biomedicine, and particularly relates to application of a TMEM65 function regulating agent in preparation of a gastric cancer cell 5-fluorouracil sensitizer. It is found for the first time that compared with control gastric cancer cells, the sensitivity of the gastric cancer cells without TMEM65 to 5-fluorouracil is increased, and under the same condition, the activity of TMEM65 deletion type gastric cancer cells is remarkably reduced by 5-FU. Furthermore, siRNA for targeted inhibition of expression of gastric cancer cells TMEM65 is combined with 5-FU, so that the proliferation activity of the gastric cancer cells can be greatly reduced. The invention can be used for solving the problem that a patient subjected to gastric cancer chemotherapy is insensitive to 5-FU treatment or has drug resistance, improving the gastric cancer chemotherapy effect and providing reference for research and development of gastric cancer chemotherapy effect drug combination.

The present application relates to a kind of multifunctional layered double hydroxide (LDH) based therapeutic nano vaccine and preparation method and application.The nano vaccine is loaded with immunoadjuvant CpG and chemotherapeutic drug 5-fluorouracil (5-FU) in turn with LDH as carrier, and further coated with apoptotic tumor cell membrane (aCM), to construct a nano vaccine with immune synergistic therapy function.After being injected into mouse body through tail vein, the LDH-based therapeutic nano vaccine realizes multi-mode combined therapy for tumor through the endoplasmic reticulum stress amplification effect mediated by calcium ion overload, through 5-FU to inhibit DNA synthesis and interfere RNA function in tumor cells, and through the synergistic immune activation mechanism mediated by the double adjuvant system composed of aluminum ion and CpG.The strategy not only significantly inhibits the growth of in situ tumor, but also can induce the body to produce immune memory, and plays an effective tumor prevention effect.

The invention belongs to the technical field of biomedical materials, and particularly relates to a drug-loaded microneedle patch for inhibiting keloid hyperplasia and a preparation method of the drug-loaded microneedle patch. The drug-loaded microneedle patch comprises the following raw materials in parts by weight: 100 parts of an antioxidant polymer carrier, 1-5 parts of 5-fluorouracil, 0.5-3 parts of triamcinolone acetonide, 1-4 parts of a cross-linking agent and 30-60 parts of a biocompatible polymer, the antioxidant polymer carrier is composed of hyaluronic acid, ROS responsive cross-linking bridge molecules and Prussian blue nanoparticles, and the microneedle adopts a core-shell structure design. A shell layer is loaded with a quick-acting anti-proliferation drug 5-fluorouracil, a core layer is loaded with a long-acting anti-inflammatory drug triamcinolone acetonide, and the cross-linking density of the core layer is higher than that of the shell layer, so that time-divided release of the drugs is realized, and the constructed drug-loaded microneedle patch can respond to a scar microenvironment to remove excessive active oxygen and synergistically inhibit keloid hyperplasia.

The invention relates to the technical field of biology, discloses a method for improving the yield of fluorouracil through site-specific mutagenesis and application, and provides mutant cytosine deaminase containing a specific mutation site by modifying cytosine deaminase through a gene recombination technology and a site-specific mutagenesis technology. And a recombinant bacterium capable of expressing the enzyme in a host cell is constructed. The mutant enzyme or recombinant bacteria are used as a catalyst, 5-flucytosine is used as a substrate, catalytic reaction is performed under mild reaction conditions, and 5-fluorouracil is synthesized. The invention solves the problems of low flucytosine conversion efficiency, complex process flow and the like in the prior art, the catalytic efficiency of the mutant enzyme is improved, the enzyme consumption and the reaction time are reduced, and the production cost is effectively reduced. The method disclosed by the invention is efficient and economical, and the obtained mutant enzyme not only can be used for producing 5-fluorouracil in the field of medicines, but also has the potential of being applied to the fields of biosensors, environmental monitoring and the like.

The invention discloses a nano-carrier for precise sequential controlled release of a synergistic drug and a preparation method. The preparation method comprises the following steps: preparing a prussian blue nano-cage loaded with 5-fluorouracil; the outer layer of the Prussian blue nanocage is coated with the methotrexate functionally modified hyaluronic acid; and constructing a co-delivery carrier 5-FU (at) PB Cage / MTX loaded with a synergistic drug. The carrier triggers MTX release in a tumor site slightly acidic environment; after a required time interval, near-infrared light is applied to the enriched part of the carrier, the local temperature is increased by means of the photothermal conversion effect of PB Cage, the phase change material is promoted to melt and flow out, and then controllable release of 5-FU is achieved. The problems that a traditional co-delivery carrier is disordered in time sequence and poor in synergistic effect are solved, a brand new carrier design thought is provided for precise tumor chemotherapy, and important theoretical and application values are achieved for promoting conversion of nano-drugs from basic research to clinic, improving tumor treatment efficiency and reducing toxic and side effects.

The invention belongs to the technical field of biological medicines, and discloses application of berberine as a prophylactic agent in preparation of a medicine for preventing 5-fluorouracil induced intestinal mucosal injury. Based on the natural advantages of multiple targets and low toxicity of berberine, berberine is used as a preventive for preventing 5-FU induced intestinal mucosal injury for the first time, a core injury mechanism is targeted through a pre-administration mode, novel prevention and treatment strategies and drug candidates are provided for clinic, and the berberine has important clinical conversion value and application prospects. The prevention effect of berberine pre-administration on 5-fluorouracil induced intestinal mucosal injury is disclosed for the first time, and a brand-new clinical treatment mode of berberine is developed. As a natural product, berberine has good human body tolerance and relatively high safety, does not affect the anti-tumor curative effect of 5-fluorouracil when being combined with 5-fluorouracil, shows a certain anti-tumor effect in animal experiments, and is expected to improve the chemotherapy dose intensity and patient compliance.

The application provides a gastric cancer prognosis marker and application thereof, and belongs to the technical field of biotechnology.The survival analysis is carried out to explore the prognosis correlation of m6A "writer" RBM15 in gastric cancer.The results prove that RBM15 is a prognosis marker related to better clinical results, and can be used to judge the prognosis of gastric cancer patients.The application verifies the relationship among RBM15, ECT2 and EMT signal pathway, and the results prove that RBM15 mediates the m6A methylation of ECT2 through IGF2BP3, influences the stability of ECT2 RNA, thereby influences the expression of ECT2, and simultaneously regulates the EMT signal pathway.The application also discloses the mechanism that RBM15 influences the proliferation, invasion, migration and sensitivity to 5-fluorouracil chemotherapy of gastric cancer cells, and provides a new treatment target for gastric cancer treatment.

This invention provides a kit based on a three-phase enzyme-linked immunosorbent assay (ELISA) and its application. The construction of the three-phase ELISA sensor in the kit mainly includes the following steps: first, selecting a hydrophobic substrate, washing and pretreating it; second, immobilizing the coated antigen and oxidase on the substrate. This invention develops a competitive immunoassay method based on a three-phase substrate and applies it to the detection of 5-fluorouracil. This invention utilizes the specific immunoreaction between a collaboratively developed 5-fluorouracil monoclonal antibody and the antigen to quantitatively detect 5-fluorouracil, improving the selectivity for the target analyte. This immunosensor uses inexpensive equipment, is easy to operate, has high detection efficiency, simple sample processing, and exhibits a wide linear range and a high detection upper limit, making it easy to popularize and cost-effective, thus possessing high practical value.